OncoMatch/Clinical Trials/NCT06145308

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Is NCT06145308 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for salivary gland carcinoma.

Treatment: Cohort 1 (HER2-positive, RC48-ADC) · Cohort 2 (NTRK-fusion or NTRK-mutant) · Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone) · TROP2 ADC · TKI · Albumin-paclitaxel + platinum · Albumin-paclitaxel + carboplatin + apatinib + camrelizumab · albumin-bound paclitaxel+trastuzumab+pyrotinib · HER2,trastuzumab deruxtecan± pertuzumab · AR,darolutamide + goserelin+pertuzumab/trastuzumab · AR,darolutamide +goserelin +docetaxel · ivonescimab + investigator-choice platinum doublet+ · iparomlimab + tuvonralimab · cadonilimab · CDK4/6 inhibitor+AI or fulvestrant · alpelisib+fulvestrant · PARP inhibitor · enfortumab vedotin · HER2, pyrotinib + pertuzumab/trastuzumab — Patients with salivary gland carcinoma were divided into groups according to HER2, NTRK, AR, TROP-2, etc. Patients in different groups were given precision targeted therapy or chemotherapy to evaluate the efficacy (ORR rate) and safety of precision therapy.